Chimeric Antigen Receptor News and Research

RSS

Concomitant pharmacotherapy overcomes immunotherapy challenges in aggressive blood cancer

Researchers at the University of Zurich and the University Hospital Zurich have discovered that a specific mutation in the cancer cells of an aggressive type of blood cancer can prevent novel immunotherapies such as CAR T-cell therapy from working.

21 Mar 2024

Scientists aim to understand why T cells do not sustain energy in tumors

T cells are often called "assassins" or "killers" because they can orchestrate and carry out missions to hunt down bacteria, viruses, and cancer cells throughout the body.

15 Mar 2024

Innovative CAR T cell therapy targets two proteins to combat aggressive brain tumor growth

Breakthrough in Brain Cancer Treatment: Dual-Target CAR T Cell Therapy Shows Promise in Early Clinical Trial.

15 Mar 2024

Novel approach uses patient's cells as "trojan horse" to target lung cancer cells

Lung cancer is not the most common form of cancer, but it is by far the deadliest.

23 Feb 2024

MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals

The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDe switch platform and the GoCAR platform.

22 Feb 2024

CPRIT awards MD Anderson 16 grants to support cancer research and prevention

The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.

21 Feb 2024

Innovative immunotherapy targets rare melanoma subtypes

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.

16 Feb 2024

City of Hope cures oldest person of blood cancer and achieves HIV remission

City of Hope, one of the largest cancer research and treatment organizations in the United States, treated the oldest person to be cured of a blood cancer and then achieve remission for HIV after receiving a blood stem cell transplant from a donor with a rare genetic mutation.

15 Feb 2024

Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells

The effect of Interleukin-24 (IL-24) on CSCs and CAR-T cell therapy.

14 Feb 2024

Novel approach improves CAR T-cell therapy efficacy against acute myeloid leukemia

St. Jude Children's Research Hospital scientists improved chimeric antigen receptor (CAR) T–cell immunotherapy for acute myeloid leukemia (AML), demonstrating better efficacy in the lab.

12 Feb 2024

Scientists develop safer CAR T-cell strategy for treating lymphomas

In the treatment of aggressive lymphomas and blood cancer (leukaemia), so-called chimeric antigen receptor T cells (CAR T cells) are increasingly being used.

9 Feb 2024

CAR T cells target senescent cells, improve healthspan in mice

Chimeric antigen receptor (CAR) T cells have transformed the treatment of blood cancers in recent years. And there have been positive signs the "living drugs" can be harnessed against other diseases, like autoimmune disorders.

2 Feb 2024

CRISPR revolutionized: New method edits genes directly in the body

Most approved gene therapies today, including those involving CRISPR-Cas9, work their magic on cells removed from the body, after which the edited cells are returned to the patient.

1 Feb 2024

Asimov launches LV Edge Packaging System to optimize lentivirus production

New off-the-shelf system reduces the cost and risk of lentiviral (LV) production for cell and gene therapy developers.

From Asimov 29 Jan 2024

Dr. Chao Ma: Pioneering 'Leukemia-on-a-Chip' for CAR T Cell Therapy at SLAS 2024

NewsMedical speaks with Chao Ma, Ph.D. a Research Assistant Professor at New York University Tandon School of Engineering, ahead of his presentation at SLAS 2024.

From Society for Laboratory Automation and Screening (SLAS) 29 Jan 2024

Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction

study evaluates senolytic CAR T-cell therapy targeting uPAR-positive cells in aged mice, showing its effectiveness in mitigating age-related metabolic dysfunction and offering a potential long-lasting treatment for aging-associated conditions.

28 Jan 2024

T cells can be reprogrammed to fight aging

The fountain of youth has eluded explorers for ages. It turns out the magic anti-aging elixir might have been inside us all along.

24 Jan 2024

New workflow identifies shared cancer targets, advancing immunotherapy

Researchers developed the Splicing Neo Antigen Finder (SNAF) workflow, integrating deep learning to identify shared immunogenic neoantigens in cancers, offering new targets for cancer immunotherapy, particularly in melanoma and ovarian cancer.

23 Jan 2024

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.

18 Jan 2024

Decoding blood cancer secrets to optimize CAR T therapy

Chimeric antigen receptor T-cell therapy, or CAR T, has dramatically improved the treatment of certain blood cancers. Initially approved for patients who had failed multiple lines of therapy, clinical trials have shown CAR T can be used as an earlier treatment option.

17 Jan 2024